An oncology leader views AI's most powerful near-term application as handling tedious logistical and bureaucratic tasks, not discovering novel molecules. By automating paperwork and trial planning, AI can liberate scientists to spend more time on deep, creative thinking that drives breakthroughs.

The most effective AI strategy focuses on 'micro workflows'—small, discrete tasks like summarizing patient data. By optimizing these countless small steps, AI can make decision-makers 'a hundred-fold more productive,' delivering massive cumulative value without relying on a single, high-risk autonomous solution.

AI delivers the most value when applied to mature, well-understood processes, not chaotic ones. Pharma's MLR (Medical, Legal, Regulatory) review is a prime candidate for AI disruption precisely because its established, structured nature provides the necessary guardrails and historical data for AI to be effective.

AI adoption in drug companies isn't about moonshot discovery via a single prompt. Its immediate, high-impact use is in automating and error-proofing massive regulatory documents for the FDA, where a single misplaced comma can cause costly, multi-billion dollar delays.

The most tangible ROI for AI in healthcare today isn't in complex diagnostics, but in operational efficiency. AI scribes that free up doctors, intelligent call centers that triage patients correctly, and automated claim management are solving major bottlenecks and fighting burnout right now.

Pharmaceutical giants are adopting AI not for moonshot "cure cancer" prompts, but to streamline critical, error-prone processes like compiling 10,000-page FDA documents. This mundane application prevents costly delays and accelerates time-to-market for multi-billion dollar drugs.

Research shows cognitive, accuracy-based skills (like judging if an AI-generated draft is defensible) erode far more quickly than procedural skills (like running a workflow). This means teams lose their most critical risk-management capability—the ability to spot a plausible but incorrect AI output—first.

AI tools can be rapidly deployed in areas like regulatory submissions and medical affairs because they augment human work on documents using public data, avoiding the need for massive IT infrastructure projects like data lakes.

While AI for designing novel molecules gets the hype, its practical, near-term impact is in streamlining operational tasks like summarizing medical charts, preparing SEC filings, and analyzing contracts, which are a better fit for current LLM capabilities.